Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Amin Kamrani, Amir Mehdizadeh, Majid Ahmadi, Leili Aghebati-Maleki & Mehdi Yousefi. (2019) Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. Expert Opinion on Therapeutic Targets 23:5, pages 447-456.
Read now
Read now
James P. Roy, Michael M. Halford & Steven A. Stacker. (2018) The biochemistry, signalling and disease relevance of RYK and other WNT-binding receptor tyrosine kinases. Growth Factors 36:1-2, pages 15-40.
Read now
Read now
Jiali Yang, Juan Chen, Jinxi He, Jing Li, Juan Shi, William C. Cho & Xiaoming Liu. (2016) Wnt signaling as potential therapeutic target in lung cancer. Expert Opinion on Therapeutic Targets 20:8, pages 999-1015.
Read now
Read now
Parviz Kokhaei, Farhad Jadidi-Niaragh, Abdolreza Sotoodeh Jahromi, Anders Osterborg, Håkan Mellstedt & Mohammad Hojjat-Farsangi. (2016) Ibrutinib-A double-edge sword in cancer and autoimmune disorders. Journal of Drug Targeting 24:5, pages 373-385.
Read now
Read now
Articles from other publishers (27)
Rabiya Ahsan, Mohd Muazzam Khan, Anuradha Mishra, Gazala Noor & Usama Ahmad. (2023) Protein Kinases and their Inhibitors Implications in Modulating Disease Progression. The Protein Journal 42:6, pages 621-632.
Crossref
Crossref
Xueliang Li, Zhaowei Sun, Li Wang, Qinlei Wang, Maobing Wang, Jingyun Guo, Haoran Li, MenShou Chen, Guanghua Cao, Yanan Yu, Haochen Zhong, Hao Zou, Kai Ma, Bingyuan Zhang, Guolei Wang & Yujie Feng. (2023) ROR1-AS1 might promote in vivo and in vitro proliferation and invasion of cholangiocarcinoma cells. BMC Cancer 23:1.
Crossref
Crossref
Shradheya R. R. Gupta, Tram M. Ta, Maryam Khan, Archana Singh, Indrakant K. Singh & Bela Peethambaran. (2023) Identification and validation of a small molecule targeting ROR1 for the treatment of triple negative breast cancer. Frontiers in Cell and Developmental Biology 11.
Crossref
Crossref
Zumama Khalid, Simona Coco, Nadir Ullah, Alessandra Pulliero, Katia Cortese, Serena Varesano, Andrea Orsi & Alberto Izzotti. (2023) Anticancer Activity of Measles–Mumps–Rubella MMR Vaccine Viruses against Glioblastoma. Cancers 15:17, pages 4304.
Crossref
Crossref
Haiyong Peng, Thomas Nerreter, Katrin Mestermann, Jakob Wachter, Jing Chang, Michael Hudecek & Christoph Rader. (2022) ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene 41:34, pages 4104-4114.
Crossref
Crossref
Boon kiat Lee, Yuhua Wan, Zan lynn Chin, Linyan Deng, Mo Deng, Tze ming Leung, Jian Hua & Hua Zhang. (2022) Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies. Cancers 14:15, pages 3618.
Crossref
Crossref
Michael L. Wang, Jacqueline C. Barrientos, Richard R. Furman, Matthew Mei, Paul M. Barr, Michael Y. Choi, Sven de Vos, Avyakta Kallam, Krish Patel, Thomas J. Kipps, Simon Rule, Kate Flanders, Katti A. Jessen, Hong Ren, Peter C. Riebling, Patricia Graham, Lydia King, Archie W. Thurston, Michael Sun, Elizabeth M. Schmidt, Brian J. Lannutti, David M. Johnson, Langdon L. Miller & Stephen E. Spurgeon. (2022) Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evidence 1:1.
Crossref
Crossref
Vanshika Rustagi, Garima Nagar, Pooja Mittal, Archana Singh & Indrakant Kumar Singh. 2022. Protein Kinase Inhibitors. Protein Kinase Inhibitors
597
621
.
Layla Al-mansoori, Philip Elsinga & Sayed K. Goda. (2021) Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. Biomedicine & Pharmacotherapy 144, pages 112260.
Crossref
Crossref
Haiyong Peng. (2021) Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Antibody Therapeutics 4:4, pages 222-227.
Crossref
Crossref
Meysam Moghbeli, Amir Sadra Zangouei, Zahra Nasrpour Navaii & Negin Taghehchian. (2021) Molecular mechanisms of the microRNA-132 during tumor progressions. Cancer Cell International 21:1.
Crossref
Crossref
Sarah J. Nagle, Catherine Murphree, Philipp W. Raess, Levanto Schachter, Andy Chen, Brandon Hayes‐Lattin, Eneida Nemecek & Richard T. Maziarz. (2021) Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. American Journal of Hematology 96:4, pages 455-461.
Crossref
Crossref
Xiaobin Yu & Jianming Xu. (2020) A ‘Goldmine’ for digging cancer-specific targets: the genes essential for embryo development but non-essential for adult life. Journal of Molecular Cell Biology 12:9, pages 669-673.
Crossref
Crossref
Emma H. van Schie & Renée van Amerongen. (2020) Aberrant WNT/CTNNB1 Signaling as a Therapeutic Target in Human Breast Cancer: Weighing the Evidence. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Noriko Miyake, Nobuaki Ochi, Hiromichi Yamane, Takuya Fukazawa, Tomoko Ikeda, Etsuko Yokota, Masami Takeyama, Nozomu Nakagawa, Hidekazu Nakanishi, Hiroyuki Kohara, Yasunari Nagasaki, Tatsuyuki Kawahara, Naruhiko Ichiyama, Tomoki Yamatsuji, Yoshio Naomoto & Nagio Takigawa. (2020) Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells. Lung Cancer 139, pages 170-178.
Crossref
Crossref
Michael D. Paul & Kalina Hristova. (2018) The RTK Interactome: Overview and Perspective on RTK Heterointeractions. Chemical Reviews 119:9, pages 5881-5921.
Crossref
Crossref
Yuan Mao, Li Xu, Jun Wang, Louqian Zhang, Nan Hou, Juqing Xu, Lin Wang, Shu Yang, Yan Chen, Lin Xiong, Jin Zhu, Weifei Fan & Jiaren Xu. (2019) ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway. BioFactors 45:3, pages 416-426.
Crossref
Crossref
Colin E. Correnti, George S. Laszlo, Willem J. de van der Schueren, Colin D. Godwin, Ashok Bandaranayake, Melanie A. Busch, Chelsea J. Gudgeon, Olivia M. Bates, James M. Olson, Christopher Mehlin & Roland B. Walter. (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32:5, pages 1239-1243.
Crossref
Crossref
Yong Liu, Guohui Wang, Xiangwu Yang, Pengzhou Li, Hao Ling & Shaihong Zhu. (2018) MicroRNA-27b-3p regulates function and metabolism in insulin resistance cells by inhibiting receptor tyrosine kinase-like orphan receptor 1. European Journal of Inflammation 16, pages 205873921876205.
Crossref
Crossref
Carol S. Leung. (2018) Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components. Journal of Immunology Research 2018, pages 1-10.
Crossref
Crossref
Hadi Hassannia, Mohammad Mehdi Amiri, Farhad Jadidi-Niaragh, Reza Hosseini-Ghatar, Jalal Khoshnoodi, Ramezan-Ali Sharifian, Forough Golsaz-Shirazi, Mahmood Jeddi-Tehrani & Fazel Shokri. (2018) Inhibition of tumor growth by mouse ROR1 specific antibody in a syngeneic mouse tumor model. Immunology Letters 193, pages 35-41.
Crossref
Crossref
Ping-Pin Zheng, Jin Li & Johan M Kros. (2018) Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Medicinal Research Reviews 38:1, pages 325-376.
Crossref
Crossref
Liang He, Linlin Qu, Lijing Wei, Yan Chen & Jian Suo. (2017) Reduction of miR-132-3p contributes to gastric cancer proliferation by targeting MUC13. Molecular Medicine Reports 15:5, pages 3055-3061.
Crossref
Crossref
Leili Aghebati-Maleki, Mahdi Shabani, Behzad Baradaran, Morteza Motallebnezhad, Jafar Majidi & Mehdi Yousefi. (2017) Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia. Biomedicine & Pharmacotherapy 88, pages 814-822.
Crossref
Crossref
Leili Aghebati-Maleki, Vahid Younesi, Farhad Jadidi-Niaragh, Behzad Baradaran, Jafar Majidi & Mehdi Yousefi. (2017) Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique. Human Antibodies 25:1-2, pages 57-63.
Crossref
Crossref
Xiao-Ying Zhang & Pei-Ying Zhang. (2016) Receptor tyrosine kinases in carcinogenesis. Oncology Letters 12:5, pages 3679-3682.
Crossref
Crossref
Gregory T. Wurz, Chiao-Jung Kao & Michael W. DeGregorio. (2015) Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology 8:1, pages 4-31.
Crossref
Crossref